Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

To know how much Ozempic (or a similar medication) will cost you, it’s important to know if your medical insurance will cover ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...

Singer Michael Trotter Jr of The War and Treaty, chef Franklin Becker of “Top Chef Masters,” and a beauty salon owner ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

Eli Lilly stock has advanced more than 200% over ... The situation was the same for Novo Nordisk's semaglutide, commercialized as Ozempic and Wegovy. These drugs all have produced impressive ...